Drug Trial Radar · NCT02272478
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Last checked: Nov 19, 2026Latest source record: Jan 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,600
Planned (sponsor's estimate)
Start
Oct 30, 2014
Primary completion
Feb 2021
Study completion Feb 2022
Sponsor
- Lead sponsor
- Cardiff UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK
- First posted
- Oct 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years considered fit for an intensive chemotherapeutic approach, but younger patients who may not be considered suitable for the concurrent NCRI AML Trial for younger patients may also enter. Patients for whom intensive chemotherapy is not thought suitable may enter the concurrent NCRI trial of less intensive therapy (LI1). Approximately 1600 patients will be recruited. At entry, a randomisation will compare a standard chemotherapy schedule DA (Daunorubicin/Ara-C) combined with 1 dose of Mylotarg (gemtuzumab ozogamicin, or GO) in course 1 against CPX-351. Patients who have known adverse risk cytogenetics (using Grimwade 2010 classification favourable/intermediate/adverse) at diagnosis may enter a Phase 2 evaluation of the combination of Vosaroxin plus Decitabine. Patients who achieve complete remission (CR) and who are MRD negative by flow cytometry after course one of DA will receive one further course of DA, with a randomisation to receive, either a course of DA or intermediate dose Cytarabine (IDAC) as a third course. Patients who are MRD negative by flow cytometry after course one of CPX-351 will receive up to 2 further course of CPX. Patients who fail to achieve a CR after course 1 of DA or who are MRD positive by flow cytometry or for whom MRD information is not available, are eligible to be randomised to compare DA with DA plus Cladribine (DAC) or FLAG-Ida for up to two courses of therapy. Patients who fail to achieve a CR after course 1 of CPX-351 or who are MRD positive by flow cytometry or for whom MRD information is not available are eligible to be randomised between a second course of standard dose CPX versus a repeat of the course 1 schedule. Patients receiving Vosaroxin and Decitabine are excluded from these post course 1 randomisations . Following the outcome of course 1, patients who received DA chemotherapy on course 1 will be randomised to receive further chemotherapy with the 2nd generation FLT3 inhibitor AC220. Patients randomised to AC220 will be allocated a maximum of 3 courses (short AC220) or 3 courses plus maintenance for 1 year (long AC220). Patients receiving Vosaroxin and Decitabine are excluded from this randomisation. Patients will be eligible for a non-intensive allogeneic stem cell transplant if a suitable HLA matched donor is available.
Conditions
- Acute Myeloid Leukaemia
- Myelodysplastic Syndrome
Interventions
Arm A Mylotarg plus DA Versus CPX-351Drug
Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
Arm B Vosaroxin and DecitabineDrug
If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
Arm D Small molecule or NotDrug
The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
Arm C DA V FLAG-Ida V DACDrug
If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
Arm E CPX-351 (200 V 300)Drug
If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
Arm F DA V IDACDrug
Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 1 year
- Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)Time frame: 1 month
- Duration of remission, relapse rates and deaths in first CRTime frame: 1 month
- Toxicity, both haematological and non-haematologicalTime frame: 1 month
- Supportive care requirements (and other aspects of health economics)Time frame: 6 months
Locations
87 sites in 2 countries. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Herlev and Gentofte Hospital
Copenhagen, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Odense University Hospital
Odense, Denmark · Recruiting
Roskilde Hospital
Roskilde, Denmark · Recruiting
Aberdeen Royal Infirmary
Aberdeen, United Kingdom · Recruiting
Monklands Hospital
Airdrie, United Kingdom · Recruiting
Ysbyty Gwynedd Hospital
Bangor, United Kingdom · Recruiting
Royal United Hospital Bath
Bath, United Kingdom · Recruiting
Belfast City Hospital
Belfast, United Kingdom · Recruiting
Birmingham Heartland Hospital
Birmingham, United Kingdom · Recruiting
Queen Elizabeth Hospital
Birmingham, United Kingdom · Recruiting
Blackpool Victoria Hospital
Blackpool, United Kingdom · Recruiting
Ysbyty Glan Clwyd
Bodelwyddan, United Kingdom · Recruiting
Pilgrim Hospital
Boston, United Kingdom · Recruiting
Royal Bournemouth General Hospital
Bournemouth, United Kingdom · Recruiting
Bradford Royal Infirmary
Bradford, United Kingdom · Recruiting
Bristol Haematology & Oncology Centre
Bristol, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
UHW
Cardiff, United Kingdom · Recruiting
University Hospital of Wales
Cardiff, United Kingdom · Recruiting
Cheltenham General Hospital
Cheltenham, United Kingdom · Recruiting
Countess of Chester Hospital
Chester, United Kingdom · Recruiting
St Richard's Hospital
Chichester, United Kingdom · Recruiting
University Hospital of Coventry and Warwickshire
Coventry, United Kingdom · Recruiting
Derby Teaching Hospital
Derby, United Kingdom · Recruiting
Russell Hall
Dudley, United Kingdom · Recruiting
Ninewells Hospital
Dundee, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
Royal Devon & Exeter Hospital
Exeter, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
Hairmyres Hospital
Glasgow, United Kingdom · Recruiting
The New Victoria Hospital
Glasgow, United Kingdom · Recruiting
Gloucestershire Royal Hospital
Gloucester, United Kingdom · Recruiting
Royal Free Hospital
Hamstead, United Kingdom · Recruiting
Raigmore Hospital
Inverness, United Kingdom · Recruiting
Ipswich Hospital
Ipswich, United Kingdom · Recruiting
Crosshouse & Ayr Hospital
Irvine, United Kingdom · Recruiting
Kettering General Hospital
Kettering, United Kingdom · Recruiting
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.